Vol 17, No 3 (2020)
Case report
Get Citation

The therapeutic use of mianserin

Łukasz Święcicki
DOI: 10.5603/PSYCH.2020.0021
·
Psychiatria 2020;17(3):162-165.

paid access

Vol 17, No 3 (2020)
Prace kazuistyczne

Abstract

The article presents data on the therapeutic uses of mianserin. Mianserin has been used successfully for many years to
treat depression, but it seems that its potential could be better exploited. A case report was also provided regarding
a patient with psychogenic pain and depression who was successfully treated with mianserin.

Abstract

The article presents data on the therapeutic uses of mianserin. Mianserin has been used successfully for many years to
treat depression, but it seems that its potential could be better exploited. A case report was also provided regarding
a patient with psychogenic pain and depression who was successfully treated with mianserin.

Get Citation

Keywords

mianserin, depression, pharmacotherapy

About this article
Title

The therapeutic use of mianserin

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 3 (2020)

Article type

Case report

Pages

162-165

DOI

10.5603/PSYCH.2020.0021

Bibliographic record

Psychiatria 2020;17(3):162-165.

Keywords

mianserin
depression
pharmacotherapy

Authors

Łukasz Święcicki

References (11)
  1. Coppen A, Ghose K, Rao R, et al. Mianserin and lithium in the prophylaxis of depression. Br J Psychiatry. 1978; 133: 206–210.
  2. Kotowki W, Pużyńki S. Pychofarmakologia kliniczna i doświadczalna. PZWL, Warszawa 1996.
  3. Beaumont G, Gringras M, Ankier SI. Trazodone and mianserin in general practice. Psychopathology. 1984; 17 Suppl 2: 24–29.
  4. Bucknall C, Brooks D, Curry PV, et al. Mianserin and trazodone for cardiac patients with depression. Eur J Clin Pharmacol. 1988; 33(6): 565–569.
  5. Khan MC, Bennie EH, Stulemeijer SM, et al. Mianserin and doxepin in the treatment of outpatient depression with anxiety. Br J Clin Pharmacol. 1983; 15 Suppl 2: 213S–218S.
  6. Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019; 12: CD010557.
  7. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009; 70 Suppl 6: 16–25.
  8. Moliere F, Bubrovszky M, Haesebaert F, et al. Depression resistante: les startegies de changement et d’association de medicaments antidepresseurs. Press Med. 2016; 45(3): 329–337.
  9. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999; 19(2): 177–182.
  10. Święcicki Ł, Pużyński S. Skojarzone leczenie depresji lekami przeciwdepresyjnymi i pindololem – otwarte badanie skuteczności 14 dniowej terapii. Farmakoterapia Psych Neurol. 2001; 3: 285–290.
  11. Zarse K, Ristow M. Antidepressants of the serotonin-antagonist type increase body fat and decrease lifespan of adult Caenorhabditis elegans. PLoS One. 2008; 3(12): e4062.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl